04.04
2016
Anergis Closes CHF 5 Million Financing Round Extension to Conduct the ATIBAR Trial
Anergis Closes CHF 5 Million Financing Round Extension to Conduct Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT.
> Press release Anergis